DiaMedica Therapeutics (DMAC) Insider Trading & Ownership $6.97 -0.04 (-0.53%) As of 03:44 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DiaMedica Therapeutics (NASDAQ:DMAC) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage7.30%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$11.36MNumber OfInsiders Selling(Last 12 Months)0 Get DMAC Insider Trade Alerts Want to know when executives and insiders are buying or selling DiaMedica Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DMAC Insider Buying and Selling by Quarter DiaMedica Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails8/27/2025Jan StahlbergMajor ShareholderBuy50,772$6.00$304,632.00 8/26/2025Jan StahlbergMajor ShareholderBuy59,648$6.00$357,888.00 8/25/2025Jan StahlbergMajor ShareholderBuy338,265$6.00$2,029,590.00 8/22/2025Jan StahlbergMajor ShareholderBuy59,788$5.96$356,336.48 8/21/2025Jan StahlbergMajor ShareholderBuy48,172$5.96$287,105.12 8/20/2025Jan StahlbergMajor ShareholderBuy71,107$5.86$416,687.02 8/15/2025Jan StahlbergMajor ShareholderBuy8,233$6.00$49,398.00 8/14/2025Jan StahlbergMajor ShareholderBuy70,414$5.99$421,779.86 8/13/2025Jan StahlbergMajor ShareholderBuy293,601$5.91$1,735,181.91 7/23/2025Jan StahlbergMajor ShareholderBuy1,542,857$3.50$5,399,999.50 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. (Data available from 1/1/2013 forward) DMAC Insider Trading Activity - Frequently Asked Questions Who is on DiaMedica Therapeutics' Insider Roster? The list of insiders at DiaMedica Therapeutics includes David J Wambeke, Dietrich John Pauls, Jan Stahlberg, Koch Thomas Von, Randall Michael Giuffre, and Scott Kellen. Learn more on insiders at DMAC. What percentage of DiaMedica Therapeutics stock is owned by insiders? 7.30% of DiaMedica Therapeutics stock is owned by insiders. Learn more on DMAC's insider holdings. Which DiaMedica Therapeutics insiders have been buying company stock? The following insiders have purchased DMAC shares in the last 24 months: Jan Stahlberg ($11,358,597.89), and Koch Thomas Von ($3,000,000.00). How much insider buying is happening at DiaMedica Therapeutics? Insiders have purchased a total of 3,742,857 DMAC shares in the last 24 months for a total of $14,358,597.89 bought. DiaMedica Therapeutics Key ExecutivesMr. Dietrich John Pauls MBA (Age 53)President, CEO & Director Compensation: $818.61kMr. Scott Kellen CPA (Age 59)CFO & Corporate Secretary Compensation: $485.43kDr. Kirsten L. Gruis M.D. (Age 51)M.S., Independent Consultant Compensation: $449.29kDr. Ambarish Shah Ph.D.Chief Technology OfficerMr. Dominic R. Cundari (Age 73)Chief Commercial Officer Mr. David J. Wambeke (Age 40)Chief Business Officer Dr. Lorianne K. Masuoka M.D. (Age 63)Chief Medical Officer More Insider Trading Tools from MarketBeat Related Companies Xeris Biopharma Insider Trades AbCellera Biologics Insider Trades Collegium Pharmaceutical Insider Trades LENZ Therapeutics Insider Trades Enliven Therapeutics Insider Trades Zymeworks Insider Trades Stoke Therapeutics Insider Trades Upstream Bio Insider Trades Sionna Therapeutics Insider Trades Oric Pharmaceuticals Insider Trades Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles $100 Million Buyback in Upwork Stock Follows a Strong Quarter Insiders Sell These High-Quality Stocks: Why Investors Shouldn’tCoreWeave and Madrigal's Insider Trades Flash Bullish SignalsPalantir Insider Selling: Risk Signal or Normal Activity?Loop Industries Insiders Buy Stock, Signal Confidence in Outlook This page (NASDAQ:DMAC) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersSean Hannity: Help Protect Your RetirementThis Guide to retirement protection has helped thousands protect over $3 billion dollars in retirement savings...Goldco Precious Metals | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredWhat a Former CIA Agent Knows About the Coming Collapse This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DiaMedica Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DiaMedica Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DMAC Stock Alerts